Ambrisentan and its role in the management of pulmonary arterial hypertension.
Ambrisentan is the second selective endothelin-A receptor antagonist to be licensed in Europe, and the first in the United States, for the management of pulmonary arterial hypertension (PAH). It has been shown to be clinically effective in improving exercise tolerance and functional class. Furthermore, ambrisentan is well tolerated and associated with low rates of liver toxicity and minimal interactions with other medicines commonly used to treat PAH. Overall, current data support a role for ambrisentan in the management of PAH. However, the results of longer-term follow-up studies are still required to fully assess efficacy and safety.
Macintyre
Iain M
IM
Clinical Pharmacology Unit, University of Edinburgh, The Queen's Medical Research Institute, Edinburgh, UK. imacint2@staffmail.ed.ac.uk
Dhaun
Neeraj
N
Goddard
Jane
J
Webb
David J
DJ
D000818:Animals; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004347:Drug Interactions; D065130:Endothelin A Receptor Antagonists; D005500:Follow-Up Studies; D006801:Humans; D006976:Hypertension, Pulmonary / Q000188:drug therapy* / Q000503:physiopathology; D010666:Phenylpropionates / Q000493:pharmacokinetics / Q000627:therapeutic use* / Q000633:toxicity; D011724:Pyridazines / Q000493:pharmacokinetics / Q000627:therapeutic use* / Q000633:toxicity; D044022:Receptor, Endothelin A / Q000627:therapeutic use
D000959:Antihypertensive Agents; D065130:Endothelin A Receptor Antagonists; D010666:Phenylpropionates; D011724:Pyridazines; D044022:Receptor, Endothelin A; C467894:ambrisentan